Farnesoid X receptor agonist INT-767 attenuates liver steatosis and inflammation in rat model of nonalcoholic steatohepatitis
10.2147/DDDT.S170518
Saved in:
Main Authors: | Hu, Y.-B., Liu, X.-Y., Zhan, W. |
---|---|
Other Authors: | CANCER SCIENCE INSTITUTE OF SINGAPORE |
Format: | Article |
Published: |
Dove Medical Press Ltd.
2021
|
Subjects: | |
Online Access: | https://scholarbank.nus.edu.sg/handle/10635/206484 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Similar Items
-
Drug discovery and treatment paradigms in nonalcoholic steatohepatitis
by: Noureddin, M., et al.
Published: (2021) -
HUMAN IPSC-DERIVED KUPFFER CELL-BASED MODEL FOR IMMUNE MEDIATED TOXICITY AND NONALCOHOLIC STEATOHEPATITIS
by: HUANG, XIAOZHONG
Published: (2021) -
Utility of human relevant preclinical animal models in navigating NAFLD to MAFLD paradigm
by: Chua, Damien, et al.
Published: (2023) -
Synthetic and natural Peroxisome Proliferator-Activated Receptor (PPAR) agonists as candidates for the therapy of the metabolic syndrome
by: Tan, Chek Kun, et al.
Published: (2017) -
Nonalcoholic Fatty Liver Disease and Hypercholesterolemia: Roles of Thyroid Hormones, Metabolites, and Agonists
by: Sinha, Rohit A, et al.
Published: (2022)